Valuation: Intensity Therapeutics, Inc.

Market Cap 10.17M 9.21M 8.52M 7.69M 14.49M 959M 15M 102M 40.59M 512M 38.16M 37.35M 1.63B P/E 2026 *
-0.74x
P/E 2027 * -1.35x
Enterprise Value 10.17M 9.21M 8.52M 7.69M 14.49M 959M 15M 102M 40.59M 512M 38.16M 37.35M 1.63B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.28%
Yield 2026 *
-
Yield 2027 * -
1 day-1.14%
1 week-3.33%
Current month-10.44%
1 month-9.10%
3 months-26.63%
6 months-33.52%
Current year-70.31%
1 week 2.92
Extreme 2.9201
3.39
1 month 2.8
Extreme 2.8
3.58
Current year 2.8
Extreme 2.8
11.07
1 year 2.8
Extreme 2.8
15
3 years 2.8
Extreme 2.8
286
5 years 2.8
Extreme 2.8
286
10 years 2.8
Extreme 2.8
286
Manager TitleAgeSince
Chief Executive Officer 67 31/03/2012
Director of Finance/CFO 57 10/12/2023
Corporate Officer/Principal - 31/08/2023
Director TitleAgeSince
Chairman 67 31/03/2012
Director/Board Member 60 31/05/2016
Director/Board Member 66 30/04/2018
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Free

Controller/Auditor

11,000 0.4070%
16/07/26 Free

Chief Executive Officer

78,000 2.8859%
16/07/26 Free

Director

5,500 0.2035%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-3.33%-70.57%-94.20% 10.17M
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+2.79%+10.75%+95.02% 60.62B
+0.63%+1.64%+24.25%+89.70% 55.5B
-0.29%-0.39%+10.38%+119.76% 47.58B
-0.44%-5.26%+22.23%+29.00% 43.69B
-1.80%-15.60%+144.32%+694.92% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%-3.61%+78.64%+60.70% 32.22B
+2.03%+6.81%-37.18%+407.41% 26.58B
Average +0.03%+0.56%+24.97%+151.60% 41B
Weighted average by Cap. -0.03%+0.33%+35.38%+153.72%

Financials

2026 *2027 *
Net sales - -
Net income -12.49M -11.32M -10.47M -9.45M -17.8M -1.18B -18.43M -126M -49.87M -629M -46.87M -45.88M -2B -15.51M -14.06M -13M -11.73M -22.11M -1.46B -22.88M -156M -61.93M -781M -58.21M -56.97M -2.48B
Net Debt - -
Projected Income Statement - Annual - Intensity Therapeutics, Inc.
Logo Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Employees
-
Date Price Change Volume
16/11/26 US$3.045 -1.14% 2,774
13/11/26 US$3.080 -0.65% 25,623
12/11/26 US$3.100 -5.49% 11,075
11/11/26 US$3.280 +6.15% 6,707
10/11/26 US$3.090 -1.90% 8,653
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Intensity Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.080USD
Average target price
18.67USD
Spread / Average Target
+506.06%
  1. Stock Market
  2. Stocks
  3. INTS Stock